What is Accumetrics?
Accumetrics is dedicated to enhancing the understanding of platelet function and improving the quality of care for patients undergoing antiplatelet therapies. The company provides industry-leading diagnostic tests for rapid platelet function assessment, most notably through its VerifyNow System. This innovative platform is designed to offer physicians rapid and accessible insights into an individual's response to various antiplatelet agents. The VerifyNow System addresses all major antiplatelet drugs, including those for aspirin, P2Y12 inhibitors like prasugrel and clopidogrel, and GP IIb/IIIa inhibitors such as ReoPro and Integrilin. By delivering this crucial information, Accumetrics empowers physicians to make more informed and personalized treatment decisions, thereby optimizing patient outcomes.
How much funding has Accumetrics raised?
Accumetrics has raised a total of $6M across 1 funding round:
Private Equity
$6M
Private Equity (2013): $6M with participation from Essex Woodlands Health Ventures, SightLine Partners, LLC, and RiverVest Venture Partners, LLC
Key Investors in Accumetrics
Essex Woodlands Health Ventures
EW Healthcare Partners is a healthcare growth equity firm that invests in companies across the US and Europe, focusing on driving positive change in healthcare while achieving high returns. The firm partners with experienced management teams in the pharmaceuticals, MedTech, and tech-enabled services sectors, providing capital and strategic guidance to accelerate business growth.
SightLine Partners, LLC
SightLine Partners, LLC is an investment firm. Further details on their specific investment focus are not readily available from the provided data.
RiverVest Venture Partners, LLC
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs. The firm aims to enhance patient lives, support entrepreneurs, and gain the trust of investors through its commitment to science, strategy, and innovation.
What's next for Accumetrics?
The substantial enterprise-level funding and recent strategic investment signal a strong growth trajectory for Accumetrics. This capital infusion is expected to fuel further development and market expansion for its diagnostic solutions. The company's focus on improving antiplatelet therapy management positions it for continued innovation and leadership in the medical diagnostics field. Accumetrics is poised to leverage this financial momentum to enhance its product offerings and broaden its reach, ultimately contributing to better patient care globally.
See full Accumetrics company page
